VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2020 | Duvelisib for COVID-19

John DiPersio, MD, PhD, Washington University, St. Louis, MO, outlines a study evaluating the use of duvelisib, a PI3K inhibitor, for COVID-19, an agent initially investigated due to its identification as a mediator of immune response in models for cytokine release syndrome (NCT04372602). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter